Evidence map›Paper›PMID 23453899›Full record

Trial reportBreast (Edinburgh, Scotland)2013

Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a "standard chemotherapy regimen": the CASA randomized trial.

Diana Crivellari, Kathryn P Gray, Silvia Dellapasqua, Fabio Puglisi, Karin Ribi, Karen N Price, István Láng, Lorenzo Gianni, Simon Spazzapan, Graziella Pinotti and 9 more

Open access · hybridAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Breast (Edinburgh, Scotland), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Metronomic Chemotherapy in Elderly Patients.Current oncology reports · 2024
    Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Effect of age on drug metabolism in women with breast cancer.Expert opinion on drug metabolism & toxicology · 2015
    Review
  15. Review
  16. Metronomics: towards personalized chemotherapy?Nature reviews. Clinical oncology · 2014
    Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 13 institutions in 5 countries.

Diana CrivellariMedical Oncology, Centro di Riferimento Oncologico, Aviano, Italy. Electronic address: dcrivellari@cro.it.
Kathryn P GrayInternational Breast Cancer Study Group (IBCSG) Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard School of Public Health, Boston, MA, USA.
Silvia DellapasquaResearch Unit in Medical Senology, Department of Medicine, European Institute of Oncology, Milan, Italy.
Fabio PuglisiDepartment of Medical and Biological Sciences, Medical Oncology, University of Udine, Udine, Italy.
Karin RibiQuality of Life Office, International Breast Cancer Study Group Coordinating Center, Bern, Switzerland.
Karen N PriceInternational Breast Cancer Study Group Statistical Center, Boston, MA, USA; Frontier Science and Technology Research Foundation, Boston, MA, USA.
István LángNational Institute of Oncology, Budapest, Hungary.
Lorenzo GianniDepartment of Oncology, Ospedale Infermi Rimini and Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Rimini, Italy.
Simon SpazzapanMedical Oncology, Centro di Riferimento Oncologico, Aviano, Italy.
Graziella PinottiMedical Oncology, Ospedale di Circolo and Fondazione Macchi, Varese, Italy.
Jean-Marc LüthiMedical Oncology, Spital STS AG, Thun, Switzerland.
Richard D GelberInternational Breast Cancer Study Group (IBCSG) Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard School of Public Health, Boston, MA, USA; Frontier Science and Technology Research Foundation, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
Meredith M ReganInternational Breast Cancer Study Group (IBCSG) Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
Marco ColleoniResearch Unit in Medical Senology, Department of Medicine, European Institute of Oncology, Milan, Italy.
Monica Castiglione-GertschUnité de Onco-Gynécologie médicale, Departement de Médecine Hôpitaux, Universitaires de Genève, Genève, Switzerland.
Rudolf MaibachInternational Breast Cancer Study Group Coordinating Center, Bern, Switzerland.
Manuela RabaglioInternational Breast Cancer Study Group Coordinating Center, Bern, Switzerland; Department of Medical Oncology, Inselspital, Bern, Switzerland.
Alan S CoatesInternational Breast Cancer Study Group and University of Sydney, Sydney, Australia.
Aron GoldhirschDepartment of Medicine, European Institute of Oncology, Milan, Italy.
European Institute of Oncology · ITInternational Breast Cancer Study Group · CHCentro di Riferimento Oncologico · ITFrontier Science & Technology Research Foundation · USDana-Farber Cancer Institute · USHarvard University · USHôpital Beau-Séjour · CHIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori · ITNational Institute of Oncology · HUOspedale di Circolo e Fondazione Macchi · ITSpital STS · CHUniversity of Sydney · AUUniversity of Udine · IT

Funding

IBCSG STATISTICAL CENTER--A BREAST CANCER STUDY RESOURCEU24CA075362 · NCI · DANA-FARBER CANCER INSTITUTE · PI REGAN, MEREDITH M · 1997 to 2015
$7.5M
NCI NIH HHS CA-75362NCI NIH HHS U24 CA075362
6 · The paper itself

Abstract

There is no optimal treatment for breast cancers lacking estrogen (ER) and progesterone (PgR) receptors in elderly women with co-morbidities that prevent use of "standard chemotherapy regimens" such as AC or CMF. The CASA trial studied pegylated liposomal doxorubicin (PLD) and low dose, metronomic cyclophosphamide + methotrexate (CM) for older (>65), vulnerable women with operable, ER and PgR-negative breast cancer. After two years the trial closed early, due to slow and inadequate accrual, with 77 patients (38:PLD, 36:CM, 3:nil). Sixty-eight percent completed PLD; 83% completed CM (both 16 weeks). Patients on PLD reported worse quality of life, cognitive and physical functioning than non-PLD regimens (primarily CM). At a median follow-up of 42 months, 81% of randomized patients remained free of any breast cancer recurrence. Based on our limited experience, PLD and CM may be reasonable options for further study for elderly vulnerable patients with endocrine nonresponsive breast cancer.

Indexed as

AgedAged, 80 and overAntibiotics, AntineoplasticBreast NeoplasmsChemotherapy, AdjuvantComorbidityDoxorubicinFemaleHumansLiposomesMastectomyMastectomy, SegmentalNeoplasm Recurrence, LocalPolyethylene GlycolsQuality of LifeAntibiotics, AntineoplasticDoxorubicinliposomal doxorubicinLiposomesPolyethylene Glycols

Identifiers

PMID23453899
PMCPMC3613787
OpenAlexW2099273805

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.